CD44 and neoplasm: In addition, this design enabled the nanoparticles to evade immune clearance while leveraging the platelet’s inherent affinity for tumor-associated markers: the PM’s P-selectin binds with the cancer cell surface receptor CD44, allowing the nanoplatelets to specifically capture and clear circulating tumor cells (CTCs) in both blood and lymph systems, which are key conduits for metastasis.